CD44 and malignant colon neoplasm: Indeed, in addition to the results from competition experiments with anti-CD44 blocking mAb, the selectivity of these bioconjugates was confirmed by the fact that a CD44l°w human colon cancer subline disclosed a differential susceptibility to ONCOFID-P and to ONCOFID-S respect to the related CD44high counterpart.